The immunomodulatory activity of peptides related to the DNA contacting loop of p53 protein

Journal of Peptide Science

Volumn 2, Issue 5, 1996, Pages 318-324

  Bolewska Pedyczak, Eleonora ^a   Siemion, Ignacy Z ^a   Wieczorek, Zbigniew ^b  

^a UNIVERSITY OF WROC AW   (Poland)

^b INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

Author keywords

p53 protein; Peptide immunomodulators; TP5 analogues

Indexed keywords

DNA; IMMUNOLOGICAL ADJUVANT; OLIGOPEPTIDE; PROTEIN P53;

AMINO ACID SEQUENCE; ANIMAL; ANTIBODY PRODUCTION; ARTICLE; CBA MOUSE; CELLULAR IMMUNITY; CHEMISTRY; DRUG EFFECT; GENETICS; HUMAN; IMMUNOLOGY; LEUKEMIA CELL LINE; MOLECULAR GENETICS; MOUSE; MUTAGENESIS; PROTEIN BINDING;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODY FORMATION; DNA; HUMANS; IMMUNITY, CELLULAR; JURKAT CELLS; MICE; MICE, INBRED CBA; MOLECULAR SEQUENCE DATA; MUTAGENESIS; OLIGOPEPTIDES; PROTEIN BINDING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030225189     PISSN: 10752617     EISSN: None     Source Type: Journal    
DOI: 10.1002/psc.68     Document Type: Article

References (24)

1. E. Yonish-Rouach, D. Resnitzky, J. Lotem, L. Sachs, A. Kinichi and M. Oren (1991). Wild-type p53 induces apoptosis of myeloid cells that is inhibited by interleukin-6. Nature 352, 345-347.
2. D. P. Lane and S. Benchimol (1990). p53: oncogene or anti-oncogene? Genes Dev 4, 1-8.
3. Y. Cho, S. Gorina, P. D. Jeffrey and N. P. Pavletich (1994). Crystal structure of a p53 tumour-suppressor-DNA complex; understanding tumourigenic metabolism. Science 265, 346-355.
4. A. J. Levine, M. E. Perry, A. Chang, A. Silver and D. Bittner (1994). The 1993 Walter Hubert Lecture: The role of the p53 tumour suppressor gene in tumourigenesis. Br. J. Cancer 69, 409-418.
5. D. Sidransky, A. Von Eschenbach, Y. C. Tsai, P. Jones, I. Summerhayes, F. Marshall, P. M. Green, S. R. Hamilton, P. Frost and B. Vogelstein (1991). Identification of p53 gene mutations in bladder cancers and urine samples. Science 252, 706-709.
6. T. Takahashi, M. M. Nau, I. Chiba, M. J. Birrer, R. K. Rosenberg, M. Vinocour, M. Levitt, H. Pass, A. F. Gazdar and J. D. Minna (1989). p53: a frequent target for genetic abnormalities in lung cancer. Science 246, 491-494.
7. Y. Murakami, K. Hayashi and T. Sekiya (1991). Detection of aberrations of the p53 alleles and the gene transcript in human tumour cell lines by single-strand conformation polymorphism analysis. Cancer Res 51, 3356-3361.
8. B. Bressac, M. Kew, J. Wands and M. Ozturk (1991). Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 350, 429-431.
9. I. C. Hsu, R. A. Metcalf, T. Sun, J. A. Welsh, N. J. Wang and C. C. Harris (1991). Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350, 427-428.
10. M. C. Hollstein, L. Peri, A. M. Mandard, J. A. Welsh, R. Montesano, R. A. Metcalf, M. Bak and C. C. Harris (1991). Genetic analysis of human oesophageal tumours from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations. Cancer Res 51, 4102-4106.
11. J. Bartek, R. Iggo, J. Gannon and D. P. Lane (1990). Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 5, 893-899.
12. I. Chiba, T. Takahashi, M. M. Nau, D. D'Amico, D. T. Curiel, T. Mitsudomi, D. L. Buchhagen, D. Carbone, S. Piantadosi, H. Koga, P. T. Reissman, D. J. Slamon and E. C. Holmes (1990). Mutations in the p53 gene are frequent in primary resected non-small cell lung cancer. Oncogene 5, 1603-1610.
13. I. Z. Siemion, J. Słoń and Z. Wieczorek (1995). The immunosuppressive mini-domain of human lactoferrin. J. Peptide Sci. 1, 295-302.
14. Z. Wieczorek, J. Słoń, A. Kluczyk, R. Zbozień, P. Stefanowicz and I. Z. Siemion (1995). The immunomodulatory diversity of the protein of transforming growth factor β (TGFβ) family. Int. J. Peptide Protein Res. 46, 113-118.
15. G. Matlashewski, P. Lamb, D. Pin, J. Peacock, L. Crawford and S. Benskimal (1984). Isolation and characterization of a human p43, DNA clone: expression of the human p53 gene. EMBO J. 3, 3257-3262.
16. T. Audhya, D. H. Schlesinger and G. Goldstein (1981). Complete amino acid sequences of bovine thymopoietins I, II, and III: closely homologous polypeptides. Biochemistry 20, 6195-6200.
17. T. Audhya, D. H. Schlesinger and G. Goldstein (1987). Isolation and complete amino acid sequence of human thymopoietin and splenin. Proc. Natl Acad. Sci. USA 84, 3545-3549.
18. R. I. Mishell and R. W. Dutton (1967). Immunization of dissociated spleen cell cultures from normal mice. J. Exp. Med. 126, 423-428.
19. P. H. Lagrange, G. B. Mackaness and T. E. Miller (1974). Influence of dose and route of antigen injection on the immunological induction of T cells. J. Exp. Med. 139, 528-542.
20. Z. Wieczorek, M. Zimecki, J. J. Słoń and I. Z. Siemion (1994). The immunomodulatory activity of tetra- and tripeptides of tuftsin-kentsin group. Peptides 15, 215-221.
21. M. Cebrat, Z. Wieczorek and I. Z. Siemion (1996). Immunosuppressive activity of hymenistatin I. Peptides, 17, 191-196.
22. E. Nawrocka-Bolewska, I. Z. Siemion, M. Mihelić and W. Voelter (1990). Synthesis and biological activities of new analogues of thymopoietin II. (32-36). Liebigs Ann. 245-247.
23. 5-TP5. Molec. Immunol. 28, 95-98.
24. A. Pedyczak, E. Bolewska-Pedyczak, W. Voelter and I. Z. Siemion (1994). Studies on the conformation of proline containing analogues of thymopentin. Polish J. Chem. 68, 1123-1135.